Results from the phase I/II study of the A2AR antagonist NIR178 in advanced NSCLC suggested that clinical benefit was observed in immunotherapy-exposed and -naïve patients regardless of PD-L1 status, and was well tolerated [133]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.